Poland· PL-100540819
Joenja
A leniolisib product containing leniolisib, registered in Poland by Pharming Technologies B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Leniolisib is registered in 11 of 19 countries.
Countries holding a registration under ATC L03AX22 (leniolisib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Leniolisib · ATC L03AX22
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Leniolisib
- Manufacturer
- Pharming Technologies B.V.
- Country
- Poland (PL)
- ATC code
- L03AX22
- ATC class
- Leniolisib
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Leniolisib in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJOENJAPharming Technologies B.V., Leiden
- United StatesJoenjaPharming Healthcare Inc.
- IrelandJoenja 70 mg film-coated tabletsPharming Technologies B.V.
- BelgiumJoenja 70 mgPharming Technologies
- NetherlandsJoenja 70 mg, filmomhulde tablettenPharming Technologies B.V.
- SwedenJoenja 70 mg Filmdragerad tablettPharming Technologies B.V.
- IcelandJoenjaPharming Technologies B.V.
- FinlandJoenjaPharming Technologies B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Joenja
- Liechtenstein · Joenja
- Norway · Joenja
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b372c2f3-f655-4653-99c1-65764a86a648 GET /v1/drugs/b372c2f3-f655-4653-99c1-65764a86a648?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "70 mg",
"packaging": "Rpz ¦ EU/1/26/2034/001 ¦ 167608\n1 butel. 60 tabl.",
"substance": "Leniolisib 70 mg",
"common_name": "Leniolisib",
"pl_product_id": "100540819",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about leniolisib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.